⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Figure S6 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Kunling Chen Huolun Feng Yujie Zhang Jingyuan Pei Yuyan Xu Xiangxu Wei Zhuohao Chen Zhoubin Feng Lei Cai Yong Li Liang Zhao Mingxin Pan

View at Publisher

Ask AI

Bookmark

Share

Key Points

Tumor-derived ccl16 significantly enhances the efficacy of immunotherapy in hepatocellular carcinoma.
The normalization of tumor vasculature is mediated by non-canonical signaling through the macrophage icam-1 receptor.
Findings suggest a crucial link between ccl16 and improved immunotherapy, presenting new therapeutic avenues.
The study highlights the importance of targeting tumor vasculature in enhancing treatment responses.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Research reveals that tumor-derived ccl16 normalizes tumor vasculature through macrophage icam-1, suggesting improved immunotherapy outcomes.

Abstract

CCL16-mediated vascular normalization through non-canonical receptor signaling.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21afa https://doi.org/10.1158/0008-5472.30254929

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S2 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
2Figure S7 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
3Figure S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
4Figure S8 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
5Figure S5 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025

Figure S9 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Table S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Data from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025